Reviva to Present at Lytham Partners Investor Conference
News related to:Reviva Pharmaceuticals Holdings, Inc · 2 min read
CUPERTINO, Calif., Sept. 22, 2026 /CourierPR/ -- Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH), a late-stage biopharmaceutical company focused on developing therapies for diseases with unmet medical needs, announced its participation in the Lytham Partners Fall 2026 Investor Conference. The company will be presenting its corporate strategy and progress at the virtual event, which is scheduled to take place on September 29-30, 2026.
The webcast presentation will commence at 12:30 PM ET on Tuesday, September 29, 2026, and can be accessed through the conference website at lythampartners.com/fall2026 or directly at app.webinar.net/vNl8PQxLKqg. The webcast will also be available for replay following the event.
Reviva Pharmaceuticals Holdings, Inc. will be represented by Laxminarayan Bhat, PhD, the company's Founder, President, and CEO, who will be presenting at the conference. The company’s current pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both of these candidates are new chemical entities discovered in-house.
The company has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries. These patents are expected to provide the company with significant protection and exclusivity for its product candidates.
The Lytham Partners Fall 2026 Investor Conference is a platform designed to connect public companies with the largest and most appropriate cross-section of institutional investors. The conference offers a unique opportunity for Reviva Pharmaceuticals Holdings, Inc. to communicate its corporate information and strategy to a diverse audience of investors, advisors, and analysts.
The company’s strategy to strengthen the long-term value of brilaroxazine and the potential to extend patent protection and commercial exclusivity includes the expected duration of the patents. This strategy is expected to support the company’s future regulatory submissions and the timing of its planned NDA (New Drug Application) submission.
Reviva Pharmaceuticals Holdings, Inc. is also planning a bioequivalence study and intends to initiate patient enrollment in its RECOVER-2 Phase 3 trial for brilaroxazine, a drug candidate for the treatment of schizophrenia. The company anticipates FDA feedback on its clinical trial data and regulatory strategy, with a projected timeline for the availability of trial data and clinical and regulatory timelines.
The company’s cash position is strong, and its projected cash runway is expected to support its future operations. Reviva Pharmaceuticals Holdings, Inc. is committed to maintaining compliance with the standards for continued quotation on the OTC Markets, which includes limited liquidity, increased volatility, and sporadic trading in the public market for its common stock. The company is also exploring potential partnerships and growth opportunities.
The Lytham Partners Fall 2026 Investor Conference is a significant event for Reviva Pharmaceuticals Holdings, Inc., providing a platform for the company to showcase its progress and strategy to a broad audience of investors and industry experts. The company’s participation in this conference underscores its commitment to advancing its pipeline of innovative therapies and addressing unmet medical needs in the areas of central nervous system, inflammatory, and cardiometabolic diseases.